President and Founder, Behaviorome Sciences, Inc., 2009-Present
Research Scientist, Department of Medicine, Columbia University, 2000-2008
Research Scientist, Department of Microbiology, Columbia University, 1990-2000
Assistant Professor, Department of Microbiology, Columbia University, 1982-1990
Senior Staff Associate, Department of Microbiology, Columbia University, 1980-1981
Instrument Maker, Department of Physics, Columbia University, 1965-1968
Director, Laboratory for Molecular Mechanisms in Human Diseases, Department of Medicine, St. Luke’s-Roosevelt Hospital Center, 1985-2009
Columbia University, Postdoctoral Fellow, Immunology, 1975-1979
Rutgers University, Ph. D., Quantum Chemistry, 1974
Columbia University, B. S., Physics, 1967
Dartmouth College, Mathematics, 1960-1961
Dean’s List, Dartmouth College, 1960.
Partial Academic Scholarship, Dartmouth College, 1960-1961.
Dean’s List, Columbia University, 1963-64
Full Academic Scholarship, Columbia University, 1965-1967.
Colgate-Palmolive Co. Fellowship, Rutgers University, 1971-1972.
2009 - Present
- Development of the Behaviorome concept and development of automated methods for remote monitoring of mentation and behavior based on sensors and statistical learning machines.
- Further development of the Hypo-NMDAR-ST Theory of Obsessive-Compulsive Disorder and related disorders
- Development of new classes of treatments for Obsessive-Compulsive Disorder and Body Dysmorphic Disorder predicted by the Hypo-NMDA-Receptor Signal Transduction Theory.
- First to use High-Glycine Therapy with Obsessive-Compulsive Disorder and Body Dysmorphic Disorder
1997 - 2008
- Development of the Hypo-NMDA-Receptor Signal Transduction Theory of Obsessive-Compulsive Disorder and Body Dysmorphic Disorder.
2003 – 2008
- The Cellbot Project - a robotic toolbox for cell biology using statistical learning machines for automatic cell recognition and autonomous cell manipulation and analysis.
1985 – 1997
- T-cell Recognition of Internal Images in the Idiotypic Network.
- Development of a General Model of the Idiotypic Network.
1975 – 1984
- Mechanism of T-Cell receptor antigen recognition.
- Immune Regulation and Idiotypic Networks.
- Myasthenia Gravis as an autoimmune idiotypic network disease.
- Single-cell methodology and hybridoma technology (first protein-free medium)
1968 – 1974
- The lowest triplet state and the ground state of benzoic acid – a high-resolution spectroscopic study at liquid helium temperature. Ph.D. Thesis.
Cleveland, WL, DeLaPaz, RL, Fawwaz RA, and Challop RS, "High-Dose Glycine Treatment of Refractory Obsessive-Compulsive Disorder and Body Dysmorphic Disorder in a 5-Year Period," Neural Plasticity, Volume 2009, Article ID 768398, 25 pages, doi:10.1155/2009/768398
Cleveland WL. “Crime and Punishment in the Society of Lymphocytes: A Speculation on the Structure of the Putative Idiotype Network,” In: "Anti-idiotypes, Receptors, and Molecular Mimicry” (D. S. Linthicum and N. Farid, eds.) Springer Verlag, New York, 1987.
Cleveland WL, Erlanger BF. “Hypothesis: the MHC-restricted T-cell receptor as a structure with two multistate allosteric combining sites,” Mol Immunol. 1984 Nov; 21(11):1037-46.
Cleveland WL, Wassermann NH, Sarangarajan R, Penn AS, Erlanger BF. “Monoclonal antibodies to the acetylcholine receptor by a normally functioning auto-anti-idiotypic mechanism,” Nature. 1983 Sep 1-7; 305(5929):56-7.
Cleveland WL. High dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. 9,504,665.
Cleveland WL. High dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. 9,415,030.
Cleveland WL. High dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. 8,604,080.
Long, X, Cleveland, WL, Yao, YL. Methods and systems for identifying and localizing objects based on features of the objects that are mapped to a vector. 7,958,063.
Erlanger BF, Cleveland WL, Cacalano NA. Derivatives of cyclosporine A, antibodies directed thereto and uses thereof. 5,405,785.
Erlanger BF, Cleveland WL, Cacalano NA. Derivatives of cyclosporine A, antibodies directed thereto and uses thereof. 5,350,574.
Erlanger BF, Cleveland WL. Method of producing monoclonal auto-anti-idiotypic antibodies. 5,144,010.
Edelman IS, Erlanger BF, Tsilianos E, Cleveland WL. Auto-anti-idiotypic monoclonal antibodies to steroid receptors and uses thereof. 4,818,684.
Cleveland WL, Erlanger BF. Protein-free culture medium. 4,767,704.
Journals: Science, Journal of Immunology, BMC Bioinformatics, Autoimmunity, Analytical Biochemistry
National Institutes of Health: IMAT Study Section
Department of Microbiology, Columbia University:
From 1982 thru 1997, Prof Cleveland lectured in the immunology section of the departmental course given to medical, dental, and graduate students. His lectures covered the complement system, antigen-antibody interactions, T-cell immunology, and Types II-IV hypersensitivity. He also taught courses for graduate students, such as Introductory Immunology and Advanced Immunology and was on departmental committees that reviewed Ph.D. qualifying examinations and oral defenses of Ph.D. theses. Periodic lectures to House Staff in the Department of Medicine at St. Luke's-Roosevelt Hospital Center were also given.
Invited Symposium Speaker
International Symposium on “Molecular Basis of Nerve Activity” in Berlin-Dahlem, F. R. Germany, October 1984.
International Symposium on "Hybridomas in Human Systems: Technology and Biomedical Problems,” College of Physicians and Surgeons of Columbia University, May 1985.
UCLA Symposium on "Monoclonal Antibodies and Cancer Therapy” in Park City, Utah, January 1985.
International Symposium on "Anti-Idiotypes as Probes for the Study of Receptors” in Montebello, Canada, July 1986, Session Chairman.
American Association of Immunologists
The Harvey Society of New York
American Men and Women of Science
Marquis Who’s Who in the World
Marquis Who’s Who in Medicine and Healthcare
Last updated March 26, 2020